Table 2.
Laboratory outcomes of the patients from the two groups
| Outcome | Group A (347) | Group B (671) | P-value | |||
|---|---|---|---|---|---|---|
| P on the day of hCG trigger | 1.23 ± 0.53 | 1.37 ± 0.59 | 0.000 | |||
| E2 on the day of hCG trigger | 3454.95 ± 1708.14 | 3798.70 ± 1774.26 | 0.003 | |||
| P ≥ 1.5 ng/mL | 22.48% (78/347) | 34.58% (232/671) | 0.000 | |||
| E2 ≥ 5000 pg/mL | 15.27% (53/347) | 25.93% (174/671) | 0.000 | |||
| No. of oocytes retrieved | 10.59 ± 4.83 | 10.64 ± 4.62 | 0.872 | |||
| No. of MII oocytes | 9.40 ± 4.57 | 9.56 ± 4.46 | 0.586 | |||
| Fertilization rate, n (%) | IVF | ICSI | IVF | ICSI |
IVF P |
ICSI P |
|
64.49% (1712/2655) |
80.30% (685/853) |
66.09% (3341/5055) |
81.31% (1470/1808) |
0.157 | 0.539 | |
| Cleavage rate, n (%) |
98.41% (2359/2397) |
98.82% (4754/4811) |
0.160 | |||
| Day 3 top-quality rate, n (%) |
62.02% (1464/2359) |
63.04% (2997/4754) |
0.420 | |||
Abbreviations: hCG, human chorionic gonadotropin; E2, estrogen; P, progesterone; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; MII: metaphase II.